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Abstract 
Patients with advanced illness such as cancer, chronic obstructive pulmonary disease 
(COPD) and Parkinson’s disease experience acute symptoms and are usually prescribed 
medications to manage these, alongside drugs to treat other co-morbid, long-term conditions. 
As such, the pharmacotherapeutic burden for these patients is high and polypharmacy is 
common. Previous studies have revealed the prevalence of potentially inappropriate 
prescribing within this group of patients, and identified the need for attention to 
‘deprescribing’. Deprescribing can be defined as a process of optimization of medication 
regimens through cessation of potentially inappropriate or unnecessary medications.  Patients 
usually have reservations about taking medications and may be willing to discontinue one or 
more medications considered ‘inappropriate’. Similarly, healthcare professionals experience 
some challenges discussing deprescribing with patients with advanced illness. This article 
reviews research on prescribing medicines to patients with advanced illness, focusing on the 
identification of the prevalence of inappropriate or unnecessary medicines to the initiation of 
the deprescribing process. The review demonstrates the paramount importance of further 
research exploring the perspective of healthcare professionals and patients on the subject of 
deprescribing to facilitate its further acceptance in practice. 
 
 
 
 
 
 
 
 3 
Healthcare systems across the world care for a large number of people with advanced 
illness, some of who will die from their condition(s).  Illnesses termed as advanced are those 
occurring when one or more conditions become serious enough that general health and 
functioning decline, and treatments begin to lose their impact.[1] In 2012, out of 56 million 
deaths across the world, approximately 38 million (68%) were due to advanced non-
communicable illnesses, including cancer, cardiovascular disease, Parkinson's disease, 
chronic obstructive pulmonary disease (COPD).[2] These advanced illnesses, which are 
usually life limiting, are often accompanied with acute symptoms, such as pain, 
breathlessness and fatigue.  As a consequence, many patients with advanced illness are 
prescribed medication to manage these symptoms.[3]  In addition, it is also common for such 
patients to have multiple co-morbidities – many of which require the use of chronic 
medication to treat, maintain, or reduce the probability of developing associated 
complications.[4]  As such, polypharmacy is commonly observed in patients with advanced 
illness.[5]  Indeed, it has been shown that in the last year of life, the number of medications a 
patient uses significantly increases.[6] The increased pharmacotherapeutic burden associated 
with polypharmacy can result in non-adherence to prescribed treatment, as well as increased 
risk of developing drug-related toxicities through drug-drug interactions. Furthermore, as 
patients approach end of life, the way in which they respond to medications changes – this is 
mainly due to altering pharmacokinetic parameters of such patients (e.g. declining renal 
function);[7] this can, in theory, further increase the probability of developing a drug-related 
toxicity. 
In view of these challenges, it has been recommended that medication use in patients 
with life-limiting illness should be regularly evaluated to identify potentially inappropriate or 
unnecessary medications, to reduce polypharmacy, and the risks and challenges associated 
with it.  Tools such as the Beers criteria,[8] the Medication Appropriateness Index [9] and the 
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Screening Tool of Older Person's Prescriptions (STOPP) criteria [10] have been developed to 
assist healthcare professionals in their decision-making with regards to prescribing 
medication. The utility of these approaches has been demonstrated in research focusing on 
reducing inappropriate medication in an elderly population (>65 years of age).[11] Another, 
perhaps more conceptual approach, has been the development of a framework to assess 
medication appropriateness specific for patients late in life.[12] This approach provides the 
health professional with a number of factors – such as remaining life expectancy and goals of 
care – that should be considered when prescribing medication to patients with diminished life 
expectancy. 
Another consideration of appropriate medication use in patients with life-limiting 
illness is the ‘time to benefit’ – a term used within the framework proposed by Holmes and 
colleagues [12] and defined as the time for a population to realise the intended effect of the 
medication.[13] The ‘time to benefit’ of some medications commonly prescribed to manage 
co-morbid illness ranges from several months to years. For example, statins are often 
prescribed for the primary prevention of cardiovascular disease and have no specific benefit 
from a symptom point of view for patients.  The estimated time to benefit of statins is more 
than 2 years, depending on indication and outcome. In many cases, this may extend beyond 
the patient's life expectancy, which raises questions over the risk: benefit ratio of treatment. 
Indeed, and in view of this, several studies have shown that statins are inappropriately 
prescribed to patients who have life limiting illness.[14] Other inappropriately prescribed 
medications reported in the literature include: mineral and vitamin supplements; anti-
platelets; anti-hypertensive; and, anti-diabetic agents.[14] Discontinuation of these 
medications on the basis of remaining patient life expectancy will help minimise 
polypharmacy, as well as potential drug interactions and hence may have positive 
implications for patient safety and quality of life.  How these medicines are discontinued is 
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important, as abrupt discontinuation in certain circumstances may result in symptom 
recurrence or adverse drug withdrawal events. 
One approach to reducing inappropriate medication use among patients with advanced 
illness is to decide initially not to prescribe medication for the treatment of co-morbidities. 
Another approach is the process of ‘deprescribing’, which is a way of rationalising 
medications that provide limited benefit to patients.[15] Medications may be deprescribed for 
reasons of non-adherence, lack of efficacy, actual or potential adverse drug reactions, or 
development of a contraindication – all of which are circumstances that may arise in the 
management of older patients, as well as patients with life-limiting illness. To support the 
deprescribing approach, Woodward et al developed a 5-step patient-centred deprescribing 
process, which engages patients throughout the process with the aim of improving health 
outcomes:[16] this approach includes obtaining an accurate medication history; identifying 
medications that could be stopped; planning a regimen for deprescribing; working with 
patients and carers; and review and support the patient. A more recent article by Scott and 
colleagues, describe the development of a 5-step protocol to deprescribing.[17] This protocol 
also involves prioritization of drugs for discontinuation by integrating 3 criteria: those with 
the greatest harm and least benefit; those easiest to discontinue on the basis of lowest 
likelihood of withdrawal reactions or disease rebound; and, those that the patient is most 
willing to discontinue first. These criteria rank the drugs to be discontinued from high 
harm/low benefit to low harm/high benefit, with priority given to the former. 
Despite these advances, there is at present, a dearth of published empirical research 
exploring how deprescribing approaches affect the outcome for patients with advanced 
illness. One such study by Garfinkel & Mangin tested the feasibility of applying the Good 
Palliative – Geriatric Practice (GP-GP) algorithm which consists of a number of questions to 
discuss with patients/guardians in relation to the indication of the drug or possible adverse 
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reactions experienced.[18] The algorithm was applied by discontinuing medications not 
immediately essential for life in relation to the time until benefit of such medications over a 
mean follow up of 19 months. The study excluded patients whose life expectancy was less 
than 3 months.[18] In total, 256 medications were discontinued with consent from the 
patients, guardians and physicians. The study reported that, in 88 per cent of patients, the 
application of the algorithm was associated with subjective, functional, mood or cognitive 
improvement. The discontinued medicines included anti-hypertensives, aspirin, statins, 
benzodiazepines, and metformin; importantly, only 2% of the discontinued medicines were 
re-started due to symptom recurrence.[18] A similar study by the same group, involving 
elderly people in nursing departments, resulted in discontinuation of 332 medicines 
(including nitrates, antihypertensives, potassium supplements and statins). In this study, 10% 
of the medications were readministered due to relapse.[19] These finding show that when 
thinking about deprescribing, it is essential to consider the class of medication, as some 
classes of medication should not be discontinued abruptly, but tapered to prevent drug 
withdrawal events or recurrence of disease (e.g. antihypertensive medication). Focusing on 
the discontinuation of statins with patients in a palliative care setting, Kutner and colleagues 
have shown that continuing statin treatment in patients near end-of-life does not provide 
clinically significant positive (or negative) outcomes, compared to patients who have their 
statin treatment stopped.[20] In addition, the patients who discontinued statins benefited from 
improved quality of life scores, used fewer medicines, which subsequently contributed to a 
reduction in medication costs. Though the findings of this study suggests that discontinuation 
of statins prescribed for primary or secondary prevention of cardiovascular diseases in 
advanced illness is safe, it is reasonable for healthcare professionals to discuss with patients 
and their caregivers around their willingness to discontinue. 
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For the deprescribing process to be successful, both healthcare professionals and 
patients should be actively engaged in it.  Studies have shown that some general practitioners 
(GPs) find it challenging to deprescribe medications in elderly patients with multimorbidity, 
as they believe patients could perceive it as a sign of being given up on.[21]  A systematic 
review by Anderson et al highlighted perceived barriers faced by primary care physicians 
toward minimising potentially inappropriate medication; themes included: having a poor 
awareness of the appropriateness of their prescribing; inertia despite awareness that the 
prescription is potentially inappropriate; lack of self-efficacy with regards to personal ability 
to alter prescribing pattern; and, feasibility of altering prescribing in the presence of medical 
and societal health beliefs and culture, work regulations, limited resources (such as time 
constraints and reimbursement), as well as patient characteristics.[22] Prescribers usually 
have to consider a number of factors before embarking on deprescribing, as well as being 
mindful of risks of harm, blame and litigation. Considering all of these issues, the discussion 
of deprescribing by healthcare professionals for patients with advanced illness is clearly a 
sensitive and challenging issue. 
Patient perspectives are also important in this process: a recent qualitative study using 
a phenomenological approach, showed medication formed a significant part of a patient’s 
day-to-day routine; the same study also showed that there is a point in a patient’s disease 
journey where less importance is placed on taking certain medications (such as statins); this 
was also recognized by healthcare professionals who referred to it as a ‘transition’.[23]  
Further studies have shown that patients have reservations about taking medications and 
usually balance these with the perceived benefits they obtain from them.[24] Some of the 
challenges identified by patients and related to deprescribing were resistance to change and 
poor acceptability or trust in alternative options.[22] While the work of Reeve and colleagues 
revealed patients’ disagreement with the appropriateness of medication cessation, the absence 
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of a comprehensive process for discontinuation, negative influences to cease medications as 
well as fear of discontinuation are patient barriers toward deprescribing.[25] From this, it is 
evidently critical that patients are included in decisions around deprescribing and, while they 
may have concerns about the number of prescription medicines they use, the timing of a 
discussion in relation to initiating a deprescribing event – especially in patients with 
advanced illness –  appears to be is crucial.  If the timing of such a discussion is not correct, 
the patient may not be willing to change their medication regimen; this will make it 
challenging for healthcare professionals to fully engage in the deprescribing process.  
One factor that appears to be important in terms of patients engaging in deprescribing 
is the level of trust they have with their healthcare professional. Other enablers may include: 
patients’ experiences/concerns/beliefs concerning adverse effects; dislike of using multiple 
medications; and, being assured that a ceased medication can be restarted, if required.[25] 
Mindful of these factors, Reeve and colleagues used the Patients’ Attitude Towards 
Deprescribing (PATD) questionnaire to capture the views of patients regarding the number of 
medications they were taking and their willingness to discontinue some of them.[26] It was 
found that the readiness of patients to cease medications does not correlate with age, number 
of concomitant medications or number of medical conditions. The authors also found that 
more than 60 per cent of participants felt that they were taking a large number of 
medications, while 92 per cent would be willing to stop one of more medications if this was 
possible.[26]  
It is clear from the literature that an individual patient approach to deprescribing 
should be at the centre of any deprescribing decision. Indeed, Sand and colleagues revealed 
that with respect to taking medications, patients with advanced illness feared losing control, 
becoming addicted or suffering harmful effects, and as such they were mostly non-adherent 
by either skipping doses or extending dosage intervals.  This makes it clear that patients need 
 9 
to discuss their medication practice with healthcare professionals, as expected health 
outcomes can only be achieved by employing a patient-centred approach to prescribing.  
In summary, this review has identified: 1) advances in understanding the prevalence 
and detection of inappropriate medication used by patients with advanced illness; and 2) the 
processes and issues involved in discontinuation or deprescribing of such medication. The 
consideration for discontinuation of inappropriate medication in such patients is important 
when there is evidence of non-adherence, lack of efficacy, actual or potential adverse drug 
reactions, or development of a contraindication.  Qualitative research involving both patients 
and healthcare professionals has revealed the challenges around the acceptance of 
deprescribing: some healthcare professionals also find it difficult to deprescribe due to time 
constraints and the sensitivities around discussing medication discontinuation.  Patients, who 
may have concerns about the number of medicines they are prescribed, may be unwilling to 
discontinue some of them, even when suggested by their healthcare professional. In certain 
circumstances, the benefits of deprescribing medications may outweigh the risks; nonetheless 
patients should work in partnership with healthcare professionals to identify which, of any, 
medication can be stopped; this is crucial as patients are at the centre of every prescribing (or 
deprescribing) decision. The subject of deprescribing can become more practicable when all 
these challenges are carefully managed, as well as the views of all concerned are taken into 
account. The views of patients with different medical conditions on deprescribing 
‘inappropriate’ medicines may have some similarities, such as the fear of becoming addicted 
or the harmful effects of medications, but more research is needed to further explore the 
perspective of patients with life limiting illness on deprescribing in relation to different 
medical conditions, as well as various classes of medications.  
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